Dental Industry

Dental Dealers

Kovanaze is available through dental dealers that have validated cold storage and cold chain distribution to the dentists.

Upcoming Dental Meetings

April 18 – 21, 2017: American Academy of Cosmetic Dentistry (Las Vegas, NV); Booth #737

April 21-22, 2017: Pennsylvania’s Dental Meeting (Hershey, PA)

April 27-29, 2017: Star of the North Meeting (Saint Paul, MN); Booth #363

April 27-28, 2017: Utah Dental Association (Salt Lake City, UT); Booth #434

May 4-5, 2017: Texas Dental Association (San Antonio, TX); Booth #437

May 4-6, 2017: Iowa Dental Association (Cedar Rapids, IA)

May 4-6, 2017: California Dental Association (Anaheim, CA); Booth #2144

May 5-6, 2017: Mid-Atlantic Dental Meeting (Washington, DC) Booth #905

May 25-28, 2017: AAPD – American Academy of Pediatric Dentistry (Washington, DC); Booth #131

June 22-24, 2017: 2017 Florida Dental Convention (Kissimmee, FL); Booth #1305

July 13-15, 2017: Academy of General Dentistry (Las Vegas, NV)

October 19-21, 2017: American Dental Association (Atlanta, GA); Booth #519

November 24-29, 2017: Greater New York Dental Meeting (New York, NY)

Copyright © 2016 St. Renatus. All Rights Reserved.

Important Safety Information

IMPORTANT SAFETY INFORMATION: KOVANAZE is indicated for regional anesthesia when performing a restorative procedure on Teeth 4-13 and A-J in adults and children who weigh 40 kg or more. Use in patients with uncontrolled hypertension or inadequately controlled active thyroid disease of any type is not advised. Tetracaine may cause methemoglobinemia, particularly in conjunction with methemoglobin-inducing agents. Use of KOVANAZE in patients with a history of congenital or idiopathic methemoglobinemia is not advised. Methemoglobinemia should be considered if central cyanosis unresponsive to oxygen therapy occurs, especially if methemoglobinemia-inducing agents have been used. Confirm diagnosis by measuring methemoglobin level with co-oximetry. Treat clinically significant symptoms of methemoglobinemia with a standard clinical regimen. Allergic or anaphylactic reactions can occur. If an allergic reaction occurs, seek emergency help immediately. KOVANAZE is contraindicated in patients with a history of allergy to tetracaine, benzyl alcohol, other ester local anesthetics, p-aminobenzoic acid (PABA), oxymetazoline, or any other component of the product. Some clinical trial patients experienced an increase in blood pressure so blood pressure should be monitored. In addition, patients should be carefully monitored for dysphagia. KOVANAZE is not recommended for use in patients with a history of frequent nose bleeds. Concomitant use of monamine oxidase inhibitors, nonselective beta adrenergic antagonist, or tricyclic antidepressants may cause hypertension and is not recommended. Discontinue use of oxymetazoline-containing products 24 hours prior to KOVANAZE administration. Avoid concomitant use of intranasal products. The most common adverse reactions to KOVANAZE occurring in >10% of patients include a runny nose, nasal congestion, nasal discomfort, sore throat, and watery eyes.

Click here for full Prescribing Information: Package Insert

IMPORTANT SAFETY INFORMATION: Use in patients with uncontrolled hypertension or inadequately controlled active thyroid disease of any type is not advised. Tetracaine may cause methemoglobinemia, particularly in conjunction with methemoglobin-inducing agents. Use of KOVANAZE in patients with a history of congenital or idiopathic methemoglobinemia is not advised. Methemoglobinemia should be considered if central cyanosis unresponsive to oxygen therapy occurs, especially if methemoglobinemia-inducing agents have been used. Confirm diagnosis by measuring methemoglobin level with co-oximetry. Treat clinically significant symptoms of methemoglobinemia with a standard clinical regimen. Allergic or anaphylactic reactions can occur. If an allergic reaction occurs, seek emergency help immediately. KOVANAZE is contraindicated in patients with a history of allergy to tetracaine, benzyl alcohol, other ester local anesthetics, p-aminobenzoic acid (PABA), oxymetazoline, or any other component of the product. Some clinical trial patients experienced an increase in blood pressure so blood pressure should be monitored. In addition, patients should be carefully monitored for dysphagia. KOVANAZE is not recommended for use in patients with a history of frequent nose bleeds. Concomitant use of monamine oxidase inhibitors, nonselective beta adrenergic antagonist, or tricyclic antidepressants may cause hypertension and is not recommended. Discontinue use of oxymetazoline-containing products 24 hours prior to KOVANAZE administration. Avoid concomitant use of intranasal products. The most common adverse reactions to KOVANAZE occurring in >10% of patients include a runny nose, nasal congestion, nasal discomfort, sore throat, and watery eyes.

Click here for full Prescribing Information: Package Insert